Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CLPP | Q16740 | 6/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | CYBB | P04839 | 2/20 | 0.42 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.42 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354986 | 0.91 | MEN1 (0.53) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2352442 | 0.90 | ALOX5 (0.51) | CLPPALOX5COMTCYBBNOX5 | |
| SCHEMBL2347997 | 0.89 | ATM (0.59) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2348139 | 0.85 | MEN1 (0.53) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2356234 | 0.85 | MEN1 (0.53) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2358237 | 0.85 | CLPP (0.53) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2344024 | 0.83 | CYP17A1 (0.50) | CLPPGRM2COMTCYBBNOX5 | |
| SCHEMBL2346453 | 0.82 | DRD2 (0.56) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2346852 | 0.82 | DRD2 (0.56) | MEN1GAAKMT2AATMCLPP | |
| SCHEMBL2349473 | 0.82 | MEN1 (0.53) | MEN1GAAKMT2AATMCLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | claimed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | claimed |
| EP-2361912-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | claimed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| EP-2536721-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2361912-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011101805-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | MEN1 4805/4885GAA 506/4885KMT2A 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.